Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

ClinicalTrials.gov ID: NCT01949311

Public ClinicalTrials.gov record NCT01949311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD). The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment. Optional Sub-Study: The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product. The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.

Study identification

NCT ID
NCT01949311
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
2,733 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 10, 2013 (Actual)
Primary completion
Jun 27, 2022 (Actual)
Completion
Jun 27, 2022 (Actual)
Last update posted
Oct 17, 2023

2013 – 2022

United States locations

U.S. sites
129
U.S. states
35
U.S. cities
103
Facility City State ZIP Site status
Regeneron Study Site Anniston Alabama 36207 —
Regeneron Study Site Birmingham Alabama 35205 —
Regeneron Study Site 1 Birmingham Alabama 35209 —
Regeneron Study Site 2 Birmingham Alabama 35233 —
Regeneron Study Site 2 Phoenix Arizona 85018 —
Regeneron Study Site 3 Phoenix Arizona 85023 —
Regeneron Study Site 1 Phoenix Arizona 85032 —
Regeneron Study Site Fort Smith Arkansas 72916 —
Regeneron Study Site Rogers Arkansas 72758 —
Regeneron Study Site Bakersfield California 93309 —
Regeneron Study Site Clovis California 93612 —
Regeneron Study Site Costa Mesa California 92626 —
Regeneron Study Site Encinitas California 92024 —
Regeneron Study Site Fremont California 94538 —
Regeneron Study Site Lomita California 90717 —
Regeneron Study Site Long Beach California 90808 —
Regeneron Study Site 1 Los Angeles California 90025 —
Regeneron Study Site 2 Los Angeles California 90025 —
Regeneron Study Site Los Angeles California 90045 —
Regeneron Study Site Oceanside California 92056 —
Regeneron Study Site Orange California 92868 —
Regeneron Study Site Rolling Hills Estates California 90274 —
Regeneron Study Site San Diego California 92122 —
Regeneron Study Site 1 San Diego California 92123 —
Regeneron Study Site 2 San Diego California 92123 —
Regeneron Study Site Santa Monica California 90404 —
Regeneron Study Site Centennial Colorado 80112 —
Regeneron Study Site Denver Colorado 80206 —
Regeneron Study Site Denver Colorado 80220 —
Regeneron Study Site Trumbull Connecticut 06611 —
Regeneron Study Site Washington D.C. District of Columbia 20037 —
Regeneron Study Site Boca Raton Florida 33486 —
Regeneron Study Site Clearwater Florida 33756 —
Regeneron Study Site Fort Lauderdale Florida 33306 —
Regeneron Study Site 1 Jacksonville Florida 32216 —
Regeneron Study Site 2 Jacksonville Florida 32216 —
Regeneron Study Site Lake Worth Florida 33461 —
Regeneron Study Site Miami Florida 33135 —
Regeneron Study Site Miami Florida 33144 —
Regeneron Study Site Miami Lakes Florida 33016 —
Regeneron Study Site Orlando Florida 32806 —
Regeneron Study Site Tampa Florida 33607 —
Regeneron Study Site Tampa Florida 33614 —
Regeneron Study Site Tampa Florida 33624 —
Regeneron Study Site West Palm Beach Florida 33406 —
Regeneron Study Site Alpharetta Georgia 30022 —
Regeneron Study Site Atlanta Georgia 30322 —
Regeneron Study Site Columbus Georgia 31904 —
Regeneron Study Site Macon Georgia 31217 —
Regeneron Study Site Newnan Georgia 30263 —
Regeneron Study Site Sandy Springs Georgia 30328 —
Regeneron Study Site Savannah Georgia 31405 —
Regeneron Study Site Chicago Illinois 60611 —
Regeneron Study Site Normal Illinois 61761 —
Regeneron Study Site West Dundee Illinois 60118 —
Regeneron Study Site Indianapolis Indiana 46250 —
Regeneron Study Site Newburgh Indiana 47630 —
Regeneron Study Site Plainfield Indiana 46168 —
Regeneron Study Site Overland Park Kansas 66215 —
Regeneron Study Site New Orleans Louisiana 70112 —
Regeneron Study Site Rockville Maryland 20850 —
Regeneron Study Site Boston Massachusetts 02111 —
Regeneron Study Site Boston Massachusetts 02114 —
Regeneron Study Site Boston Massachusetts 02115 —
Regeneron Study Site Bay City Michigan 48706 —
Regeneron Study Site Farmington Hills Michigan 48334 —
Regeneron Study Site Troy Michigan 48084 —
Regeneron Study Site Edina Minnesota 55435 —
Regeneron Study Site Fridley Minnesota 55432 —
Regeneron Study Site Minneapolis Minnesota 55402 —
Regeneron Study Site Plymouth Minnesota 55402 —
Regeneron Study Site Saint Joseph Missouri 64506 —
Regeneron Study Site St Louis Missouri 63104 —
Regeneron Study Site St Louis Missouri 63141 —
Regeneron Study Site Henderson Nevada 89052 —
Regeneron Study Site Las Vegas Nevada 89119 —
Regeneron Study Site Portsmouth New Hampshire 03801 —
Regeneron Study Site Berlin New Jersey 08009 —
Regeneron Study Site East Windsor New Jersey 08520 —
Regeneron Study Site Verona New Jersey 07044-2946 —
Regeneron Study Site 1 Albuquerque New Mexico 87106 —
Regeneron Study Site 2 Albuquerque New Mexico 87106 —
Regeneron Study Site Buffalo New York 14203 —
Regeneron Study Site Corning New York 14830 —
Regeneron Study Site Forest Hills New York 11375 —
Regeneron Study Site New York New York 10016 —
Regeneron Study Site New York New York 10021 —
Regeneron Study Site New York New York 10029-6501 —
Regeneron Study Site New York New York 10075 —
Regeneron Study Site Rochester New York 14642 —
Regeneron Study Site Chapel Hill North Carolina 27516 —
Regeneron Study Site High Point North Carolina 27262 —
Regeneron Study Site Raleigh North Carolina 27612 —
Regeneron Study Site Wilmington North Carolina 28405 —
Regeneron Study Site Winston-Salem North Carolina 27104 —
Regeneron Study Site Cincinnati Ohio 45231 —
Regeneron Study Site Cleveland Ohio 44106 —
Regeneron Study Site Norman Oklahoma 73071 —
Regeneron Study Site Tulsa Oklahoma 74136 —
Regeneron Study Site Medford Oregon 97504-9741 —
Regeneron Study Site Portland Oregon 97223 —
Regeneron Study Site Portland Oregon 97239 —
Regeneron Study Site Bethlehem Pennsylvania 18020 —
Regeneron Study Site Jenkintown Pennsylvania 19046 —
Regeneron Study Site Philadelphia Pennsylvania 19104 —
Regeneron Study Site Pittsburgh Pennsylvania 15213 —
Regeneron Study Site Charleston South Carolina 29407 —
Regeneron Study Site Greer South Carolina 29650 —
Regeneron Study Site Chattanooga Tennessee 37421 —
Regeneron Study Site Nashville Tennessee 37215 —
Regeneron Study Site Arlington Texas 76011 —
Regeneron Study Site Austin Texas 78705 —
Regeneron Study Site Bellaire Texas 77401-3505 —
Regeneron Study Site Dallas Texas 75230 —
Regeneron Study Site Dallas Texas 75231 —
Regeneron Study Site Dallas Texas 75246 —
Regeneron Study Site Houston Texas 77004 —
Regeneron Study Site San Antonio Texas 78218 —
Regeneron Study Site 1 San Antonio Texas 78229 —
Regeneron Study Site 2 San Antonio Texas 78229 —
Regeneron Study Site San Antonio Texas 78258 —
Regeneron Study Site Waco Texas 76710 —
Regeneron Study Site Webster Texas 77598 —
Regeneron Study Site Salt Lake City Utah 84132 —
Regeneron Study Site South Burlington Vermont 05403 —
Regeneron Study Site Newport News Virginia 23606-4537 —
Regeneron Study Site Norfolk Virginia 23502 —
Regeneron Study Site Richmond Virginia 23220 —
Regeneron Study Site Seattle Washington 98101 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 303 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01949311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 17, 2023 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01949311 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →